SYDNEY, September 13, 2024 – Aurora Biosynthetics, a cutting-edge RNA therapeutics manufacturing company, has officially launched, marking a new chapter in the RNA therapeutics landscape across the Asia-Pacific region. With an emphasis on advanced RNA-based therapies, the company is set to meet the growing demand for Good Manufacturing Practice (GMP) production of plasmid DNA (pDNA), messenger RNA (mRNA), and lipid nanoparticles (LNP).
Strategic Collaboration with Key Industry Leaders
The launch of Aurora Biosynthetics is the result of a strategic public-private partnership between the New South Wales (NSW) Government, RNA Australia, and Myeloid Therapeutics, a leading innovator in RNA immunotherapies. This collaboration combines the latest RNA manufacturing technology with robust governmental support to fuel Aurora’s entry into the global market.
The NSW Government has committed AU$200 million to bolster Australia’s RNA ecosystem, including the construction costs for Aurora’s state-of-the-art facility. Located at Macquarie University in Sydney, this facility will foster collaborations with top academic researchers and create a pipeline for a highly skilled workforce, positioning Australia at the forefront of RNA therapeutic advancements.
Comprehensive RNA Manufacturing Capabilities
Aurora Biosynthetics offers a fully integrated suite of RNA manufacturing solutions, catering to the needs of the rapidly evolving therapeutic landscape. Their end-to-end services include:
- GMP Plasmid Production: Supporting cell and gene therapies, and mRNA production.
- GMP RNA Production: Specializing in the development of RNA-based therapies.
- GMP Lipid Nanoparticle Production: Offering advanced LNP encapsulation for mRNA and other active pharmaceutical ingredients (APIs).
- Fill-Finish Services: Providing final formulation and fill-finish services for both clinical trials and commercial products.
This comprehensive range of services simplifies the manufacturing process, reducing complexity and speeding up the time-to-market for clients and collaborators.
Positioning for the Future
Aurora Biosynthetics is well-placed to meet the growing demand for RNA therapeutics within the expanding field of cell and gene therapies. With a projected compound annual growth rate (CAGR) exceeding 20% in these fields, Aurora aims to become the leading GMP manufacturer in the Asia-Pacific region and beyond.
The company’s leadership team, which possesses extensive experience in RNA technology and manufacturing, is dedicated to scaling the business and securing a strong financial foundation to support its growth.
Economic Impact and Innovation Support
In addition to its comprehensive RNA manufacturing services, Aurora Biosynthetics’ clients can benefit from Australia’s R&D tax credit, which offers a 43% cashback on research and development expenditures. This incentive, coupled with the significant support from the NSW Government, makes Australia an attractive hub for RNA therapeutic development and manufacturing.
About Aurora Biosynthetics
Based in Sydney, Australia, Aurora Biosynthetics is an advanced RNA manufacturing company providing GMP production of pDNA, mRNA, and LNPs. As a subsidiary of Myeloid Therapeutics, Aurora leverages strategic partnerships and innovative technology to meet the global demand for RNA-based therapies, positioning itself as a key player in the RNA manufacturing landscape.
With a commitment to advancing RNA therapeutics and delivering superior value to its customers, Aurora Biosynthetics is poised to play a pivotal role in the future of RNA-based medicines.
Join us at the 3rd ANZ Biologics Festival 2025, set for February 5th and 6th in Melbourne, Australia. This premier event will spotlight the most exciting areas in biotechnology, featuring a stellar lineup of speakers from around the world. Dive deep into innovative topics such as next-generation biologics, breakthroughs in cell and gene therapy, and cutting-edge RNA therapeutics. Engage with thought leaders and pioneers who are shaping the future of medicine. Whether you’re looking to network, collaborate, or simply stay on the cutting edge of biopharma research, this festival is your gateway to the forefront of the industry. Don’t miss this opportunity to be part of a vibrant community driving advancements in Australia and New Zealand’s biotech sector. Find out more at https://imapac.com/events/australia-biologics-festival/
The full press release can be accessed here for those interested.
